

Myobloc

CareFirst - Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Date:
Physician Office Fax:
Physician Office Fax:
Physician Office Fax:
111 1/1 -
Phone:
☐ Same as Requesting Provider
NPI#:
Phone:
accordance with FDA-approved labeling, ence-based practice guidelines.
□ Off Campus Outpatient Hospital
!

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. CareFirst MR C26745-A, Myobloc SGM 2249-A – 06/2025.

Ex	ception Criteria Questions:
A.	The preferred products for your patient's health plan are Dysport and Xeomin. Can the patient's treatment be switched to one of the preferred products?
	 □ Yes, Please obtain Form for preferred product and submit for corresponding PA. □ No, Continue to Question B
B.	What is the patient's diagnosis? <i>Action required</i> : <i>If 'None of the above'</i> , <i>attach supporting chart note(s) indicating diagnosis</i> ☐ Chronic sialorrhea, <i>Continue to Question C</i> ☐ Cervical dystonia, <i>Skip to Question E</i> ☐ None of the above, <i>Skip to Clinical Criteria Questions</i>
C.	Is the patient 12 years of age of older? ☐ Yes, Continue to Question D ☐ No, Skip to Clinical Criteria Questions
D.	Did the patient have a documented inadequate response, intolerable adverse event, or contraindication to Xeomin? <i>Action Required: If 'Yes', Attach supporting chart note(s).</i> Yes Po, No, skip to Clinical Criteria Questions.
E.	Is the patient 18 years of age or older? ☐ Yes, Continue to Question F ☐ No Skip to Clinical Criteria Questions
F.	Did the patient have a documented inadequate response, intolerable adverse event, or contraindication to Dysport and Xeomin for cervical dystonia? <i>Action Required: If Yes, attach supporting chart note(s)</i> Yes No, <i>If Yes or No, Continue to Clinical Criteria Questions</i>
an	Inical Criteria Questions: Is therapy prescribed for cosmetic purposes (e.g., treatment of wrinkles or uncorrected congenital strabismus and no binocular fusion)? I Yes, Continue to 2 I No, Continue to 2
2.	What is the diagnosis?
	Cervical dystonia (e.g., torticollis), Continue to 3
	Chronic sialorrhea (excessive salivation), Continue to 6
	Primary axillary or palmar hyperhidrosis, Continue to 9
	Upper limb spasticity, Continue to 13
	Other, please specify, No further questions
ra	Prior to initiating therapy with the requested drug, was/is there abnormal placement of the head with limited unge of motion in the neck? Yes, <i>Continue to 4</i> No, <i>Continue to 4</i>
4. pa	Is the requested medication being prescribed by or in consultation with a provider specialized in treating the atient's condition? I Yes, <i>Continue to 5</i> I No, <i>Continue to 5</i>

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720 Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. CareFirst MR C26745-A, Myobloc SGM 2249-A - 06/2025.

5. What is the patient's age? years of age, Continue to 15
6. Is the patient refractory to pharmacotherapy (e.g., anticholinergics)? ☐ Yes, Continue to 7 ☐ No, Continue to 7
7. Is the requested drug being prescribed by or in consultation with a provider specialized in treating the patient's condition? Yes, <i>Continue to 8</i> No, <i>Continue to 8</i>
8. What is the patient's age? years of age, <i>Continue to 15</i>
 9. Has significant disruption of professional and/or social life occurred because of excessive sweating? ☐ Yes, Continue to 10 ☐ No, Continue to 10
 10. Has the patient tried topical aluminum chloride or other extra-strength antiperspirants? ☐ Yes, Continue to 11 ☐ No, Continue to 12
11. Was the topical aluminum chloride or other extra-strength antiperspirants ineffective or result in a severe rash? ☐ Yes, Continue to 12 ☐ No, Continue to 12
12. Is the requested drug being prescribed by or in consultation with a provider specialized in treating the patient's condition? Yes, <i>Continue to 15</i> No, <i>Continue to 15</i>
13. Is the spasticity a primary diagnosis or as a symptom of a condition causing limb spasticity? ☐ Yes, <i>Continue to 14</i> ☐ No, <i>Continue to 14</i>
14. Is the requested drug being prescribed by or in consultation with a provider specialized in treating the patient's condition? ☐ Yes, Continue to 15 ☐ No, Continue to 15
15. Is this request for continuation of therapy?☐ Yes, Continue to 16☐ No, No Further Questions
16. Was the requested drug effective for treating the diagnosis or condition? ☐ Yes, No Further Questions ☐ No, No Further Questions

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720 Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. CareFirst MR C26745-A, Myobloc SGM 2249-A - 06/2025.

Step Therapy Override: Complete if Applicable for the state of Maryland.		Please Circle	
Is the requested drug being used to treat stage four advanced metastatic cancer?	Yes	No	
Is the requested drug's use consistent with the FDA-approved indication or the National Comprehensive Cancer Network Drugs & Biologics Compendium indication for the treatment of stage four advanced metastatic cancer and is supported by peer-reviewed medical literature?	Yes	No	
Is the requested drug being used for an FDA-approved indication OR an indication supported in the compendia of current literature (examples: AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?	Yes	No	
Does the prescribed quantity fall within the manufacturer's published dosing guidelines or within dosing guidelines found in the compendia of current literature (examples: package insert, AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?	Yes	No	
Do patient chart notes document the requested drug was ordered with a paid claim at the pharmacy, the pharmacy filled the prescription and delivered to the patient or other documentation that the requested drug was prescribed for the patient in the last 180 days?	Yes	No	
Has the prescriber provided proof documented in the patient chart notes that in their opinion the requested drug is effective for the patient's condition?	Yes	No	

Step Therapy Override: Complete if Applicable for the state of Virginia.		Please Circle	
Is the requested drug being used for an FDA-approved indication or an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines)?	Yes	No	
Does the prescribed dose and quantity fall within the FDA-approved labeling or within dosing guidelines found in the compendia of current literature?	Yes	No	
Is the request for a brand drug that has an AB-rated generic equivalent or interchangeable biological product available?	Yes	No	
Has the patient had a trial and failure of the AB-rated generic equivalent or interchangeable biological product due to an adverse event (examples: rash, nausea, vomiting, anaphylaxis) that is thought to be due to an inactive ingredient?	Yes	No	
Is the preferred drug contraindicated?	Yes	No	
Is the preferred drug expected to be ineffective based on the known clinical characteristics of the patient and the prescription drug regimen?	Yes	No	
Has the patient tried the preferred drug while on their current or previous health benefit plan and it was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?	Yes	No	
Is the patient currently receiving a positive therapeutic outcome with the requested drug for their medical condition?	Yes	No	

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

Χ	
Prescriber or Authorized Signature	Date (mm/dd/yy)